全球干细胞治疗市场 – 行业趋势及 2030 年预测

干细胞治疗市场分析及规模

世界卫生组织 (WHO) 估计，脑血管疾病和神经系统疾病约占全球疾病负担的 7.1%。因此，企业正在进行基础研究和临床前研究，以检验干细胞在治疗神经系统疾病方面的再生能力。癌症的细胞治疗目前正从企业获得大量资金，预计这将支持市场扩张。

Data Bridge Market Research 分析，干细胞治疗市场在 2022 年的规模为 2.57 亿美元，预计到 2030 年将达到 9.2112 亿美元，在 2023 年至 2030 年的预测期内复合年增长率为 17.3%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

干细胞治疗市场范围和细分  

Market Definition

Stem cell therapy is regenerative medicininal therapy used to repair damaged cells by lowering inflammation and controlling the immune system. This makes stem cell therapy an effective remedy for several illnesses. Studies on stem cell therapies for Crohn's disease, Multiple Sclerosis, Lupus, COPD, Parkinson's, ALS, stroke recovery, and more have been undertaken. Stem cell therapies have also been utilized to treat autoimmune, inflammatory, neurological, orthopedic, and traumatic disorders.

Stem Cell Therapy Market Dynamics

Drivers

• The rise in prevalence and incidence of chronic diseases will drive the market growth

The majority of people around the world suffer from chronic ailments. One in three adults worldwide has a chronic illness. Chronic diseases have impacted the health and quality of life of many people. Chronic illnesses, such as cancer, musculoskeletal and neurological conditions, chronic injuries, cardiovascular and gastrointestinal conditions, and cancer, can result in hospitalization, long-term incapacity, a decline in quality of life, and even death.

The mesenchymal stem cells penetrate and integrate into several organs, treat lung, spinal cord, autoimmune disorders, liver, bone, and cartilage diseases, and treat multiple organ damage. Using stem cells in the therapy of inflammatory, immune system, and degenerative tissue illnesses is an effective strategy.

• The growing need for potent treatments will propel the market growth

One of the key drivers of market expansion is significant R&D investments. In addition, the growing need for potent treatments to reduce disease burden during the forecast period is another factor fuelling the growth. For instance, the 5-year exploratory study on Parkinson's illness by Celavie Biosciences is still ongoing as of May 2020. For the treatment of Parkinson's disease and other illnesses of the central nervous system, the business is developing regenerative stem cell therapies. Ok99 stem cell-based exploratory clinical studies for Parkinson's disease were effective, according to Celavie Biosciences.

Opportunities

• An increase in R&D activities will act as an opportunity

Additionally, the increase in R&D activities and rising investments from public and private organizations will open up new possibilities for the market's growth rate. For instance, U.S. healthcare spending increased by 3.4% in 2021, per the Health Care Price Index (HCPI). The rise in growth indicates that federal spending fell sharply the year before, from USD 287,000 million in 2020 to USD 170,000 million in 2021.

The prompt treatment of chronic illnesses has increased the demand for stem cell therapy in the U.S. and Europe. Due to these positive elements, there is a greater need for drugs, and both major and minor market players are employing various techniques to meet this demand.

• A strategic initiative by market players will widen the scope of growth

The leading companies are also working to develop targeted strategies, including product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth operation of the business, minimize risks, and boost the market's long-term growth in sales.

For instance,

To create and market the search-use-only (RUO) microfluidic intracellular delivery technology, ViaCyte, Inc. teamed up with SQZ Biotechnologies in May 2022. Through the agreement, both market participants will be able to share fresh cell engineering research in hematopoietic stem cells.

Restraints/Challenges

• The high cost of treatment hinders the market expansion

Cell treatment market expansion has been hampered by its high cost. As people search for the newest therapy choices, cell treatments have emerged as a popular treatment option. Cell treatments are still exceedingly expensive to try, despite the enormous rise in demand for them. Depending on the situation, simple joint injections might cost up to $1,000, and more complex operations can cost up to $100,000. In the U.S., the average price of stem cell therapy is projected to be between $4,000 and $8,000 per patient in 2020. Therefore, the growth of the stem cell therapy market is restrained by the high cost of the treatment.

This stem cell therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the stem cell therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, A worldwide licensed agreement and strategic collaboration between Minovia Therapeutics, Ltd. and Astellas Pharma, Inc. was established for the development of cutting-edge stem cell therapy programs for illnesses brought on by mitochondrial malfunction. The partnership intends to accelerate the development of allogeneic mitochondrial cell therapy initiatives. The two businesses will collaborate to investigate potential cell treatment program prospects using Astellas' genetically modified, induced pluripotent stem cells and Minovia's MAT platform technology.

Global Stem Cell Therapy Market Scope

The stem cell therapy market is segmented based on type, usage, end-user, and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Bone Marrow Derived Mesenchymal Cells
• Placental or Umbilical Stem Cell
• Adipose Tissue Derived Mesenchymal Stem Cells
• Others

 Type

• Allogenic Stem Cell Therapy
• Autologous Stem Cell Therapy

Application

• Musculoskeletal Disorders
• Acute Graft-Versus-Host Disease (AGVHD)
• Wounds and Injuries
• Cardiovascular Diseases
• Surgeries
• Gastrointestinal Diseases
• Others

 End User

• Hospitals
• Surgical Centers
• Therapeutic Companies
• Services Companies
• Others

 Distribution Channel

• Direct Tender
• Third Party Distributors

Stem Cell Therapy Market Regional Analysis/Insights

The stem cell therapy market is analysed and market size insights and trends are provided by country, type, usage, end-user and application as referenced above.

The countries covered in the stem cell therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the stem cell therapy market because of the region's well-developed healthcare infrastructure and favourable reimbursement policies. Another factor contributing to the region's growth is the number of government initiatives to promote stem cell therapy.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030, owing to the growing incidence of cancer cases, rising technological advancements, and rising prevalence of chronic diseases such as diabetes, cancer, and neurological disorders.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和干细胞治疗市场份额分析

干细胞治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对干细胞治疗市场的关注有关。

干细胞治疗市场的一些主要参与者包括：

• Athersys Inc.（美国）
• Mesoblast Ltd (澳大利亚)
• Biorestorative Therapies Inc.（美国）
• Pluristem Inc.（以色列）
• Brainstorm Cell Limited.（美国）
• ViaCyte Inc.（美国）
• Gamida Cell（美国）
• HOPE BIOSCIENCES（美国）
• 细胞生物医学集团（美国）
• Smith+Nephew（英国）
• MEDIPOST（韩国）
• ANTEROGEN. CO, LTD.（韩国）
• NuVasive Inc.（美国）
• RTI 外科 (美国)
• AlloSource（美国）
• JCR制药有限公司（日本）
• 武田药品工业株式会社 (日本)

SKU-24573